Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2023 | 1 |
2024 | 1 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
Pediatr Blood Cancer. 2023 Dec;70(12):e30672. doi: 10.1002/pbc.30672. Epub 2023 Sep 14.
Pediatr Blood Cancer. 2023.
PMID: 37710306
Clinical Trial.
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.
Pilbeam KL, Pradhan K, Croop J, Minard CG, Liu X, Voss SD, Isikwei E, Berg SL, Reid JM, Fox E, Weigel BJ.
Pilbeam KL, et al.
Pediatr Blood Cancer. 2024 Mar;71(3):e30817. doi: 10.1002/pbc.30817. Epub 2024 Jan 8.
Pediatr Blood Cancer. 2024.
PMID: 38189770
Clinical Trial.
Item in Clipboard
Cite
Cite